SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings and guidance are the main focus, with traders watching for signs that engagement, subscriber growth and advertising can offset concerns about content quality, recent layoffs and the content leadership change. Views are split between traders bracing for another post-earnings drop and bulls arguing that pessimism is already reflected in the share price.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is tied to enthusiasm for its Merck-partnered personalized melanoma vaccine after positive Phase 3 topline results, with traders focused on the detailed data presentation at ESMO. Bulls see validation of a broader cancer-vaccine platform and momentum, while bears argue expectations and valuation are stretched and warn of a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Traders are citing a reported ClinicalTrials.gov update adding a site to Sareptas ENHANCE Elevidys safety study as a possible trigger for the rebound, though they note the study timeline reportedly slipped. The broader debate centers on whether upcoming DM1 and FSHD data can support a recovery, with some traders pointing to short covering and others stressing that those clinical results remain unproven.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plans to pursue a public listing for fintech arm Monee and launch Sea Cloud are fueling concern about spending and uncertainty. Traders largely blame the developments for the selloff, while some see a Monee listing as a potential way to unlock value for shareholders.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and higher outlook have been met with a sharp selloff, prompting traders to question why strong demand and orders are not lifting the shares. The debate centers on rising costs, weaker cash conversion and an insurance loss, while some investors view the reaction as excessive given the improved guidance.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention after its quarterly earnings beat and improved cash-flow outlook failed to prevent a sharp selloff, as traders focused on narrowed full-year profit guidance with no increase to its midpoint. Some see the new buyback and cash generation as support for the shares, while others argue the outlook disappointed despite the strong quarter.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash proceeds as a potential balance-sheet and strategic reset. Others argue the divestiture removes a significant revenue stream and leaves concerns about debt and weakness in the remaining business; the transaction is still pending approval and closing.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

A sharp COMP rally and stronger volume have fueled talk of a technical reversal, with traders pointing to chart patterns and a possible breakout. Bulls see renewed momentum, while skeptics question whether the move can hold given COMPs history of lagging other crypto assets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Upcoming MSToronto clinical presentations are driving attention, especially initial Phase 1 azer-cel results in progressive MS alongside BRIUMVI data on long-term outcomes and dosing. Traders are broadly optimistic about the catalyst-rich pipeline and BRIUMVIs commercial growth, while some caution that azer-cel is early-stage and debate the stocks muted trading; buyout speculation remains unconfirmed.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports shares are drawing attention after RAP-219s Phase 2 bipolar-mania trial met its primary and secondary endpoints, prompting bullish reactions and analyst upgrades. Traders are debating whether the efficacy signal is strong enough to justify the surge, citing the modest placebo-adjusted improvement, higher discontinuation rate, and the stocks sharp retreat after its initial jump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?

Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.read more...

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion.
Filana Therapeutics (NASDAQ:FLNA) shares roseread more...

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?

Equity

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.


After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Key PointsThe chief medical officer of Monte Rosa Therapeutics reported selling 41,845 shares directly for a transaction value of approximately $882,000, based on a weighted average price of around $21.08 per share over June 23-24, 2026...

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-monte-rosa-therapeutics-inc-stock...

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 15,837,633 shares...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating an...

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.</li><li>The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with related programs. &nbsp;</li><li>While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;</li></ul>Shares of BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) plunged on Friday after Novo Nordisk’s (NVO) late-stage trial setback raised concerns about biotech stocks pursuing similar approaches to treating heart disease through inflammation reduction. &nbsp;BIOA tumbled 64%, while GLUE dropped about 27%. BIOA clocked its worst day since December 2024, while GLUE booked its worst day ever.<h2 class="st-heading-2">NVO’s Trial Miss</h2>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS. The once-monthly treatment was designed to lower the risk of heart attacks, strokes, and related deaths in patients with heart and kidney problems plus high inflammation. While the drug successfully reduced inflammation markers as expected, it showed no benefit in cutting those major heart events compared with a placebo. The study involved more than 6,300 patients.Novo said the miss will not change its 2026 profit outlook and that two other trials of the same drug will continue. NVO shares closed 9% lower on Friday.The result also raised questions about whether targeting inflammation this way can meaningfully protect the heart, pressuring companies with related programs such as BioAge and Monte Rosa. While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;<h2 class="st-heading-2">Wall Street Weighs In</h2>Analysts weighed in on BioAge, whose lead candidate BGE-102 targets a similar approach as ziltivekimab. Jefferies cut its price target to $21 from $62 but kept a Buy rating, saying the “outright” failure raises biological risk for a key inflammation marker as a heart-risk signal. The firm still sees potential differentiation for BGE-102, but called its profile harder to predict now.Citi noted BIOA’s greater-than-60% drop and agreed the data is a negative for BioAge’s heart-disease thesis, yet argued the size of the move “seems overdone” with the company’s enterprise value nearing zero. Citi maintains a Buy rating and $52 price target.Roth Capital’s Adam Walsh lowered his price target to $25 from $36 while keeping a Buy rating. The firm now sees lower chances that a partner will fund a heart trial for BGE-102 or that it will succeed, but its estimates for the same drug in eye disease stay the same. &nbsp;The new price targets on BIOA represent a potential upside of 132% to 475% from the stock’s Friday close.Jefferies also cut its price target on Monte Rosa (GLUE) to $25 from $40, still implying a potential upside of 51% from the last close, and kept a Buy rating. Success in the ZEUS trial would have supported Monte Rosa’s approach to residual inflammation in heart disease with its experimental drug MRT-8102, so the miss is “a setback.” The firm still sees prospects in other indications and other pipeline value drivers. &nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BIOA improved from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high levels.’Meanwhile, sentiment around GLUE stock rose from ‘neutral’ to ‘bullish,’ accompanied by a rise in retail chatter.A Stocktwits user termed the selloff on Friday as an “oversold play” and voiced hopes for a recovery in the next few days.<stembedurl>https://www.stocktwits.com/Gemini367/message/660591844</stembedurl>While <a href="https://stocktwits.com/symbol/BIOA">BIOA stock</a> has fallen 32% year-to-date, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> has gained 5%.&nbsp;Read more: <a href="https://stocktwits.com/news-articles/markets/equity/tmus-stock-slips-as-300-b-deutsche-telekom-merger-talks-reportedly-hit-a-roadblock/cZN4lirRJP6">TMUS Stock Slips As $300B Deutsche Telekom Merger Talks Reportedly Hit A Roadblock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAge Labs logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with rel

BioAge Labs Inc.

Novo Nordisk A/S

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$11.18
Prev Close	$10.66
Open	$10.74
Dividend Yield	0.00%
50-Day Moving Average	$12.91
Beta	1.45
Avg. Volume	1.12M
PE Ratio	-5.59

52-Week High	$25.77
52-Week Low	$8.94
Market Capitalization	$909.44M
EPS (Annual)	-$0.465
Price to Book	1.86
Revenue Per Employee	$824,480.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLUE Fundamentals